Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Page 1
Small Arteriovenous Anastomosis in Fistula Creation: Establishing a Functional Vascular Access while Minimizing Steal Syndrome.
Turner MA, Mathlouthi A, Patel RJ, Perreault M, Malas MB, Al-Nouri O. Turner MA, et al. Ann Vasc Surg. 2024 Feb;99:142-147. doi: 10.1016/j.avsg.2023.10.002. Epub 2023 Nov 4. Ann Vasc Surg. 2024. PMID: 37926140
Larger studies with longer follow-up are needed to evaluate long-term outcomes of small anastomosis fistulas....
Larger studies with longer follow-up are needed to evaluate long-term outcomes of small anastomosis fistulas....
Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.
Hill LF, Clements MN, Turner MA, Donà D, Lutsar I, Jacqz-Aigrain E, Heath PT, Roilides E, Rawcliffe L, Alonso-Diaz C, Baraldi E, Dotta A, Ilmoja ML, Mahaveer A, Metsvaht T, Mitsiakos G, Papaevangelou V, Sarafidis K, Walker AS, Sharland M; NeoVanc Consortium. Hill LF, et al. Among authors: turner ma. Lancet Child Adolesc Health. 2022 Jan;6(1):49-59. doi: 10.1016/S2352-4642(21)00305-9. Epub 2021 Nov 26. Lancet Child Adolesc Health. 2022. PMID: 34843669 Free PMC article. Clinical Trial.
The use of the optimised regimen cannot be recommended because a potential hearing safety signal was identified; long-term follow-up is being done. These results emphasise the importance of robust clinical safety assessments of novel antibiotic dosing regimens in infants. …
The use of the optimised regimen cannot be recommended because a potential hearing safety signal was identified; long-term follow-up …
Reinvestigating the Photoprotection Properties of a Mycosporine Amino Acid Motif.
Whittock AL, Turner MAP, Coxon DJL, Woolley JM, Horbury MD, Stavros VG. Whittock AL, et al. Among authors: turner map. Front Chem. 2020 Sep 25;8:574038. doi: 10.3389/fchem.2020.574038. eCollection 2020. Front Chem. 2020. PMID: 33102444 Free PMC article.
We show that by 1.8 ns, there is >75% electronic ground state recovery of ACyO, with the remaining percentage likely persisting in the electronic excited state. Long-term irradiation studies on ACyO have shown that a small percentage degrades after 2 h of irradiation, p …
We show that by 1.8 ns, there is >75% electronic ground state recovery of ACyO, with the remaining percentage likely persisting in the el …
An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial.
Hill LF, Turner MA, Lutsar I, Heath PT, Hardy P, Linsell L, Jacqz-Aigrain E, Roilides E, Sharland M; NeoVanc Consortium. Hill LF, et al. Among authors: turner ma. Trials. 2020 Apr 15;21(1):329. doi: 10.1186/s13063-020-4184-8. Trials. 2020. PMID: 32293527 Free PMC article. Clinical Trial.
Secondary endpoints include clinical/microbiological relapse/new infection at the short-term follow-up visit (30 5 days after the initiation of vancomycin), evaluation of safety (renal/hearing), vancomycin PK and assessment of a host biomarker panel over the course of vanc …
Secondary endpoints include clinical/microbiological relapse/new infection at the short-term follow-up visit (30 5 days after the ini …
Challenges in developing a consensus definition of neonatal sepsis.
McGovern M, Giannoni E, Kuester H, Turner MA, van den Hoogen A, Bliss JM, Koenig JM, Keij FM, Mazela J, Finnegan R, Degtyareva M, Simons SHP, de Boode WP, Strunk T, Reiss IKM, Wynn JL, Molloy EJ; Infection, Inflammation, Immunology and Immunisation (I4) section of the ESPR. McGovern M, et al. Among authors: turner ma. Pediatr Res. 2020 Jul;88(1):14-26. doi: 10.1038/s41390-020-0785-x. Epub 2020 Mar 3. Pediatr Res. 2020. PMID: 32126571 Review.
Similar initiatives in neonatology are likely to be more challenging and would need to account for the unique presentation of sepsis in term and premature neonates. The outputs of similar consensus work within neonatology should be twofold: a validated definition of neonat …
Similar initiatives in neonatology are likely to be more challenging and would need to account for the unique presentation of sepsis in t …
Neurodevelopmental Outcomes at 42 Months After Thyroxine Supplementation in Infants Below 28 Weeks' Gestation: A Randomized Controlled Trial.
Ng SM, Turner MA, Weindling AM. Ng SM, et al. Among authors: turner ma. Thyroid. 2020 Jul;30(7):948-954. doi: 10.1089/thy.2019.0293. Epub 2020 Mar 17. Thyroid. 2020. PMID: 32070246 Free PMC article. Clinical Trial.
Infants were either supplemented with LT4 started intravenously during the first 5 days after birth and then changed to oral LT4 when enteral feeds were fully established (8 mug/kg birthweight/day as a single daily dose) or given placebo until 32 weeks' corrected gestation …
Infants were either supplemented with LT4 started intravenously during the first 5 days after birth and then changed to oral LT4 when …
Big Data in the Assessment of Pediatric Medication Safety.
McMahon AW, Cooper WO, Brown JS, Carleton B, Doshi-Velez F, Kohane I, Goldman JL, Hoffman MA, Kamaleswaran R, Sakiyama M, Sekine S, Sturkenboom MCJM, Turner MA, Califf RM. McMahon AW, et al. Among authors: turner ma. Pediatrics. 2020 Feb;145(2):e20190562. doi: 10.1542/peds.2019-0562. Epub 2020 Jan 14. Pediatrics. 2020. PMID: 31937606
Randomized clinical trials within the regulatory context may not enroll patients who are representative of the general pediatric population, provide the power to detect rare safety signals, or provide long-term safety data. BD sources may have these capabilities. In recent …
Randomized clinical trials within the regulatory context may not enroll patients who are representative of the general pediatric population, …
A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction.
Sharp A, Jackson R, Cornforth C, Harrold J, Turner MA, Kenny L, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorghiou AT, Alfirevic Z. Sharp A, et al. Among authors: turner ma. Eur J Obstet Gynecol Reprod Biol. 2019 Oct;241:109-118. doi: 10.1016/j.ejogrb.2019.08.007. Epub 2019 Aug 16. Eur J Obstet Gynecol Reprod Biol. 2019. PMID: 31499415 Clinical Trial.
Effect of sildenafil on maternal hemodynamics in pregnancies complicated by severe early-onset fetal growth restriction: planned subgroup analysis from a multicenter randomized placebo-controlled double-blind trial.
Khalil A, Sharp A, Cornforth C, Jackson R, Mousa H, Stock S, Harrold J, Turner MA, Kenny LC, Baker PN, Johnstone ED, Von Dadelszen P, Magee L, Papageorghiou AT, Alfirevic Z. Khalil A, et al. Among authors: turner ma. Ultrasound Obstet Gynecol. 2020 Feb;55(2):198-209. doi: 10.1002/uog.20851. Ultrasound Obstet Gynecol. 2020. PMID: 31432556 Free article. Clinical Trial.
CONCLUSIONS: Sildenafil in a dose of 25 mg three times daily increases HR, reduces BP and reduces arterial stiffness in pregnancies complicated by severe early-onset FGR. These changes are short term, modest and consistent with the anticipated vasodilatory effect. They hav …
CONCLUSIONS: Sildenafil in a dose of 25 mg three times daily increases HR, reduces BP and reduces arterial stiffness in pregnancies complica …
Assessment of long-term neurodevelopmental outcome following trials of medicinal products in newborn infants.
Marlow N, Doyle LW, Anderson P, Johnson S, Bhatt-Mehta V, Natalucci G, Darlow BA, Davis JM, Turner MA; International Neonatal Consortium (INC). Marlow N, et al. Among authors: turner ma. Pediatr Res. 2019 Nov;86(5):567-572. doi: 10.1038/s41390-019-0526-1. Epub 2019 Aug 9. Pediatr Res. 2019. PMID: 31398720 Free PMC article. Review.
There is significant uncertainty over the role of assessment of long-term neurodevelopmental outcome (LTO) in neonatal clinical trials. ...
There is significant uncertainty over the role of assessment of long-term neurodevelopmental outcome (LTO) in neonatal clinical trial …
40 results